Validation of the Use of the Arteriovenous Tension Difference in CO2 Under Hyperbaric Conditions
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity Hospital, Lille
About this trial
The central venous-arterial carbon dioxide tension difference is used daily in intensive care to establish peripheral tissue hypoperfusion, mainly mediated by a low cardiac index.
The partial pressures of gases (oxygen, carbon dioxide) increase in the blood of patients breathing 100% oxygen in hyperbaric conditions.
Thus, the validity of this biomarker in situations of acute circulatory failure during a hyperbaric oxygen therapy session has not been established.
The objective of the study is therefore to establish the diagnostic performance of the central venous-arterial carbon dioxide tension difference in the diagnosis of a low cardiac index in patients with septic shock undergoing hyperbaric oxygen therapy for necrotizing fasciitis.
Eligibility criteria
Qualifiers
Diagnosis of necrotizing fasciitis complicated by septic shock as defined by the Surviving Sepsis Campaign
Indication for HBOT according to the criteria of the 2016 European Consensus Conference
Patient intubated and ventilated prior to the HBOT session, receiving intravenous sedation at doses sufficient to be in a passive ventilation state
Patient equipped with a central venous line in the superior vena cava allowing central venous blood gas analysis
Disqualifiers
- Minors
Pregnant women
Persons deprived of their liberty (prisoners, persons under guardianship or trusteeship)
Persons not affiliated with or not covered by a social security system
Trial design
Treatments tested in this trial
- Echography
Treatment groups
74 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov